By Colin Kellaher
Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the clinical-stage biopharmaceutical company reported positive results from a pair of Phase 2 studies assessing the potential of its NE3107 drug candidate in Parkinson’s disease and Alzheimer’s disease.
The Carson City, Nev., company said the study of NE3107 in Parkinson’s met both main objectives, with patients treated with a combination of the drug and levodopa seeing meaningful improvements in their motor score and an absence of adverse interactions of NE3107 with levodopa.
BioVie said that based on the study findings, it will proceed with planning the Phase 3 program for discussion with the U.S. Food and Drug Administration.
Meanwhile, BioVie said patients treated with NE3107 in the Alzheimer’s study experienced improved cognition and biomarker levels, with no drug-related adverse events observed.
BioVie shares, which closed Monday at $5.21, were recently up 15% to $5.98 in premarket trading.
Write to Colin Kellaher at [email protected]
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/tronc/4LPIPV7WVDMO7GL5PYUCBWFCN4.jpg)
